Physician profile
Jie He
NPI 1124259353
$26,067.08
in general payments reported to CMS, 2019-2025
61 companies · $4,741 in 2025
The $4,741 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,727 · 2020: $2,504 · 2021: $3,915 · 2022: $3,739 · 2023: $3,833 · 2024: $3,608 · 2025: $4,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,181.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,064.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $3,871.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $2,447.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,648.25 | 2019-2025 | Tezspire, Farxiga |
| Amneal Pharmaceuticals LLC | $1,633.65 | 2019-2025 | Unithroid |
| Corcept Therapeutics | $1,395.50 | 2019-2025 | Korlym |
| Abbvie INC. | $920.48 | 2019-2025 | |
| Gilead Sciences, INC. | $887.14 | 2019-2025 | Vemlidy, Livdelzi, Yeztugo |
| Bayer Healthcare Pharmaceuticals INC. | $871.42 | 2022-2025 | |
| Dexcom, INC. | $730.44 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Amgen INC. | $695.49 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $511.53 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.03 | 2019-2025 | Jardiance, Tradjenta |
| Vivus LLC | $411.89 | 2020-2024 | Qsymia |
| Insulet Corporation | $384.62 | 2019-2025 | Omnipod, Omnipod |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $380.60 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $303.93 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $256.57 | 2020-2023 | |
| Zealand Pharma US, INC. | $246.96 | 2021-2022 | |
| Antares Pharma, INC. | $238.31 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Cequr Corporation | $224.43 | 2023-2025 | Cequr Simplicity |
| Pfizer INC. | $208.18 | 2019-2025 | |
| Radius Health, INC. | $207.16 | 2019-2024 | Tymlos |
| Ibsa Pharma INC. | $196.44 | 2019-2024 | Licart, Tirosint, Tirosint |
| Shire North American Group INC | $181.17 | 2019 | |
| Glaxosmithkline, LLC. | $168.57 | 2025 | Arexvy, Shingrix |
| Mannkind Corporation | $167.37 | 2020-2025 | |
| Genentech USA, INC. | $165.15 | 2019 | |
| Astellas Pharma US INC | $142.93 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.24 | 2019-2023 | Cycloset |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| Noven Pharmaceuticals, INC. | $124.99 | 2024 | Xelstrym |
| Eisai INC. | $124.98 | 2024 | |
| Medtronic, INC. | $121.35 | 2021-2023 | Minimed 770g |
| Beta Bionics, INC. | $101.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ars Pharmaceuticals Operations, INC. | $100.00 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $96.33 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $95.67 | 2019-2020 | |
| Medtronic Minimed, INC. | $86.26 | 2019 | |
| Medtronic USA, INC. | $86.02 | 2019 | |
| Vertos Medical, INC. | $77.74 | 2019 | |
| Ascendis Pharma Endocrinology INC | $65.46 | 2025 | Yorvipath |
| Takeda Pharmaceuticals U.S.A., INC. | $65.10 | 2020-2021 | |
| Lifescan, INC. | $57.91 | 2021-2022 | |
| Sequel Med Tech, LLC | $54.20 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $42.26 | 2020-2024 | Signifor Lar, Isturisa |
| Horizon Therapeutics Plc | $41.42 | 2022-2023 | Tepezza |
| Alvogen INC | $41.31 | 2022-2024 | Teriparatide |
| Currax Pharmaceuticals LLC | $31.87 | 2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $22.37 | 2024 | |
| Almatica Pharma LLC | $22.36 | 2025 | Teriparatide |
| Halozyme INC | $20.29 | 2023 | |
| Janssen Pharmaceuticals, INC | $19.87 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $19.58 | 2023 | |
| Rgh Enterprises LLC | $19.43 | 2024 | |
| Acerus Pharmaceuticals Corporation | $16.25 | 2022 | |
| Verity Pharmaceuticals INC. | $15.97 | 2025 | Tlando |
| Eusa Pharma (US) LLC | $15.29 | 2022 | |
| Ascensia Diabetes Care US INC. | $15.28 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $15.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.